CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically in Medical – Diagnostics & Research. The company describes itself as a full-service, non-clinical global drug development partner. Its work spans research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing support products and services, supporting clients from target identification through non-clinical development and product release. For 2025, total revenue was $4.0 billion, split among three reportable segments: Research Models and Services (RMS) at 21.1%, Discovery and Safety Assessment (DSA) at 59.8%, and Manufacturing Solutions at 19.1%. The company currently operates over 120 sites across more than 20 countries.

The negative margin profile—net margin of -6.0% and ROE of -7.7%—is the central tension in assessing its competitive position. A leading global footprint with an integrated, multi-segment portfolio normally points to scale advantages, yet these figures show that leadership has not recently translated into bottom-line profitability. That combination suggests the moat is real in terms of breadth and client relationships, but it is currently being offset by restructuring costs, acquisition integration, or pricing pressures rather than by a lack of market position.

Financial posture

Charles River Laboratories carries a market capitalization of $14.4 billion, but its P/E ratio is -61.7 because the company is not currently profitable. The negative net margin and negative ROE confirm that posture: earnings are in the red rather than expanding. At the same time, the stock’s beta is 1.38, meaning it has historically moved more sharply than the broader market.

The current price is $298.58, with a 50-day EMA of $242.40 and an RSI of 77.4. That RSI level is technically deep in overbought territory, while the gap between the current price and the 50-day EMA is unusually wide. Those metrics, combined with the negative P/E, describe a stock whose price action has outrun its current earnings power. The valuation cannot be judged on trailing earnings alone; investors are instead weighing the strategic restructuring, demand for outsourced drug development, and whether margins can turn positive.

Strategic priorities & outlook

The company’s most recent 10-K outlines a near-term agenda built on consolidation and integration rather than expansion for its own sake. Management intends to optimize the global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally within DSA and RMS. At the same time, it is folding Discovery Services and Safety Assessment into one overarching DSA organization with a combined sales force and leadership structure.

The stated strategic objective is to become the scientific partner of choice by delivering a comprehensive, integrated portfolio that can accelerate biomedical research and therapeutic innovation. A more concrete growth vector is the expansion of Biologics Testing Solutions service offerings and facilities in the U.S. and Europe. In January 2026, the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. Taken together, the plan is to shrink the physical footprint while strengthening the scientific offering and supply chain for higher-growth biologics testing.

Macro & geopolitical exposure

As a Healthcare/Medical – Diagnostics & Research company, Charles River Laboratories is exposed to biopharmaceutical research-and-development spending cycles, which are sensitive to interest rates and biotech funding availability. The company also operates under strict regulatory oversight—FDA, EMA, and GLP standards affect every stage of its safety assessment and manufacturing support work.

With more than 120 sites in over 20 countries, geographic diversification is accompanied by currency translation risk and cross-border supply-chain complexity. Because research models, including non-human primates, are sourced internationally, the business is exposed to animal-welfare regulation, import/export controls, and potential trade restrictions or tariffs. Pricing pressure from large pharmaceutical customers and shifts in government-funded research budgets are additional macro-level variables that can affect demand and margins across the contract research and manufacturing services landscape.

Recent developments

On August 24, 2026, Great Lakes Advisors LLC disclosed a new $459,000 investment in Charles River Laboratories, according to defenseworld.net. That same week, Zacks.com published two pieces highlighting the stock’s momentum: on August 21, 2026, it noted CRL had jumped 33.3% in the prior month, and on August 21, 2026, it also reported Charles River had gained 88.6% over the past year. The Zacks headlines pose the rally as a question rather than a forecast, but they confirm the recent price strength visible in the technical metrics. One unrelated item in the same news scan, dated August 20, 2026, concerned John Rogers reducing a stake in Sphere Entertainment Co., which has no direct bearing on Charles River.

Earnings behavior & post-earnings drift

Charles River Laboratories has beaten earnings estimates in each of the last eight reported quarters, for a 100% beat rate, with an average earnings surprise of 9.3%. The average 5-day price move in the trading sessions after those reports has been +1.24%, classified as an upward post-earnings drift.

The last four reports illustrate how uneven that drift can be, even when the headline beat is consistent:

• August 5, 2026: actual EPS of $3.02 versus an estimate of $2.74—a 10.2% surprise. The stock rose 1.84% the next day and 9.07% over the following five days.
• May 7, 2026: actual EPS of $2.06 versus an estimate of $1.96—a 5.1% surprise. The stock fell 2.23% the next day and 12.42% over the following five days.
• February 18, 2026: actual EPS of $2.39 versus an estimate of $2.33—a 2.6% surprise. The stock rose 3.95% the next day and 6.05% over the following five days.
• November 5, 2025: actual EPS of $2.43 versus an estimate of $2.32—a 4.7% surprise. The stock rose 1.9% the next day and 2.27% over the following five days.

The next scheduled earnings release is November 4, 2026, before the market open, with a consensus EPS estimate of $2.97. The beat streak is firmly established, but the May 2026 example shows that an earnings beat does not guarantee a positive immediate reaction, especially after a strong run-up.

For a deeper dive into how institutional analysts, options positioning, and multi-factor models currently view Charles River Laboratories, review the full institutional verdict on the ticker page rather than relying on any single headline or quarter.